From Wikipedia, the free encyclopedia
Jump to: navigation, search
Structural formula of arsthinol
Systematic IUPAC name
119-96-0 N
ChemSpider 8107 YesY
EC Number 204-361-7
Jmol 3D model Interactive image
Interactive image
KEGG D07356 YesY
PubChem 8414
Molar mass 347.28 g·mol−1
P01AR01 (WHO) QP51AD01 (WHO)
89 % Hepatic[1]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite)[2] and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years later by Endo Products (Balarsen, Tablets, 0.1 g).[3] Among trivalent organoarsenicals, arthinol was considered as very well tolerated.[4] Recently, it was studied for its anticancer activity.[5][6]


  1. ^ Cristau, B; Chabas, ME; Placidi, M (1975). "Voies et cinétiques d'excrétion de l'arsenic chez le Cobaye après injection de divers médicaments organo-arséniés". Ann Pharm Fr 33: 577–89. 
  2. ^ Friedheim EAH. (1949) A Five Day Peroral Treatment of Yaws with STB, a New Trivalent Arsenical. Am J Trop Med Hyg s1-29: 185
  3. ^ Anonyme (1953). "New and nonofficial remedies; arsthinol". J Am Med Assoc 152: 531. 
  4. ^ Brown, CH; Gebhart, WF; Reich, A (1956). "Intestinal amebiasis: incidence, symptoms, and treatment with arsthinol (Balarsen)". JAMA 160: 360–363. doi:10.1001/jama.1956.02960400018005. 
  5. ^ Gibaud, S; Alfonsi, R; Mutzenhardt, P; et al. (2006). "(2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity". J Organomet Chem 691: 1081–1084. doi:10.1016/j.jorganchem.2005.11.007. 
  6. ^ Becherirat, S.; Lanhers, M.-C.; Socha, M.; Yemloul, M.; Astier, A.; Loboda, C.; Aniceto, N.; Gibaud, S. (2013). "The antitumor effects of an arsthinol-cyclodextrin complex in an heterotopic mouse model of glioma". Eur J Pharm Biopharm 85: 560–568. doi:10.1016/j.ejpb.2013.06.021.